{"classes":["LITERATURE REFERENCE","PRIMARYSOURCECOUNTRY","REPORTERORGANIZATION","REPORTERCOUNTRY","PATIENTONSETAGE","PATIENTSEX","RESULTSTESTSPROCEDURES","PATIENTDRUGNAME","PATIENTDRUGINDICATION","PATIENTDRUGREACTION","PRIMARYSOURCEREACTION","MEDICINALPRODUCT","REPORTERDEPARTMENT","PATIENTDEATHREPORT","REACTIONSTARTDATE","PATIENTAGEGROUP","SERIOUSNESSOTHER","SERIOUSNESSHOSPITALIZATION","REPORTERGIVENAME","REPORTERFAMILYNAME","REPORTERSTREET","REPORTERCITY","REPORTERPOSTCODE","TESTNAME","TESTRESULT","DRUGDOSAGEFORM","DRUGADMINISTRATIONROUTE","DRUGINDICATION","DRUGSTARTPERIODUNIT","SERIOUSNESSLIFETHREATENING","TESTUNIT","MEDICALHISTORYEPISODE","PATIENTPASTDRUGTHERAPY","DRUGSTRUCTUREDOSAGEUNIT","REPORTERMIDDLENAME","REPORTERSTATE","SERIOUSNESSDEATH","ACTIONDRUG","DRUGDOSAGETEXT","DRUGSTRUCTUREDOSAGENUMB","PATIENTWEIGHT","SUSPECTPRODUCT","CONCOMITANTPRODUCT","PATIENTHEIGHT","DRUGINTERVALDOSAGEDEFINITION","INTERACTINGPRODUCT","PATIENTMEDICALHISTORYTEXT","PASTDRUGNAME","PATIENTMEDICALSTARTDATE","REACTIONENDDATE"],"annotations":[["Therapie (2018) 73, 551—553\r\nAvailable online at\r\nwww.sciencedirect.com\r\nLETTER TO THE EDITOR\r\nDiclofenac induced drug rash with\r\neosinophilia and systemic symptoms\u0002\r\nKEYWORDS\r\nDiclofenac;\r\nAdverse drug reaction;\r\nDRESS syndrome;\r\nPharmacovigilance\r\nAbbreviations\r\nDRESS drug rash with eosinophilia and systemic symptoms\r\nCMV cytomegalovirus\r\nEBV Epstien Barr virus\r\nHIV human immunodeficiency virus\r\nNSAID non steroidal anti-inflammatory (drugs)\r\nRegiSCAR European registry of severe cutaneous adverse\r\nreactions\r\nIntroduction\r\nDrug rash with eosinophilia and systemic symptoms (DRESS)\r\nsyndrome is a severe, potentially life-threatening condition\r\nwith a mortality rate of about 10%. This syndrome is charac\u0002terized by the clinical association of fever, rash, and internal\r\norgan involvement [1]. It has been associated with aromatic\r\nanticonvulsants, sulfonamides and allopurinol.\r\nNon steroidal anti inflammatory (NSAI) drugs have been\r\nrarely reported as a causative agent in DRESS syndrome.\r\nWe report the first case of DRESS syndrome associated\r\nwith diclofenac.\r\nCase report\r\nA 53-year-old woman, with asthma complained of back\r\npain and she took diclofenac 50 mg daily on January 2018.\r\nTen days after starting the treatment, she presented with\r\nfever, cough and multiple lymphadenopathy. She stopped\r\ndiclofenac and was prescribed amoxicilline, paracetamol,\r\nmefenamic acid and cetirizine. One day following the first\r\nintake of these drugs, she developed generalized rash\r\n\u0002 This case was notified to the Tunisian center of pharmacovigi\u0002lance of Tunis (Tunisia) on January 30th 2018.\r\ninvolving the trunk and the members. She was admitted to\r\nthe hospital.\r\nClinical examination revealed temperature at 39.5 ◦C,\r\ngeneralized maculopapular pruritic rash, cervical, axillary\r\nand inguinal lymph nodes.\r\nBlood tests showed high white blood cells count\r\n13490/mm3 and 1830/mm3 eosinophils. Plasmatic creati\u0002nine level was increased at 213 \u0002mol/L. Liver enzymes were\r\nnormal.\r\nSerology for Epstein Barr virus (EBV), cytomegalovirus\r\n(CMV) and human immunodeficiency virus (HIV) were neg\u0002ative.\r\nHistological findings were compatible with DRESS syn\u0002drome.\r\nDRESS syndrome was confirmed and all the medications\r\nwere stopped except cetirizine.\r\nSkin condition improved slowly and laboratory parame\u0002ters returned to normal level in about 16 days.\r\nDiscussion\r\nThe diagnosis of DRESS syndrome was made in this patient\r\nbased on the criteria adopted by the European registry of\r\nsevere cutaneous adverse reactions group (RegiSCAR) [2]. In\r\nour case, the RegiScar score was 5 (probable case): general\u0002ized skin rash (1), eosinophilia (2), kidney involvement (1)\r\nenlarged lymph nodes (1).\r\nDiclofenac was suspected to be the responsible drug\r\nfor the DRESS syndrome in this case based on the French\r\nmethod of imputation [3]. The score for diclofenac was\r\nI2.\r\nIn literature, NSAIDs have been rarely reported with\r\nDRESS syndrome as a causative agents [4—11]. It was associ\u0002ated with piroxicam, ibuprofen, celecoxib, phenylbutazone,\r\nsulfasalazine and dipyrone (Table 1).\r\nIn the case reported by Lee, patch tests were positive to\r\nboth celecoxib and ethambutol [6]. The authors could not\r\nconclude about responsibility of the two drugs in inducing\r\nDRESS syndrome.\r\nAs our patient developed hypersensitivity one day after\r\nstarting amoxicilline, paracetamol, mefenamic acid and cet\u0002irizine, a possible co-sensitization with diclofenac remains\r\npossible despite the short delay.\r\nIt has been suggested that DRESS episode may induce\r\na massive non-specific activation of the immune system,\r\nwhich will provide the enhanced expression of costimulatory\r\nmolecules and proinflammatory cytokines. The latter will\r\nallow a more efficient presentation of chemical antigens\r\nto antigen-presenting cells and consequently decrease\r\nthe level of tolerance to drugs present at the time in the\r\n552 Letter to the Editor\r\nTable 1 Summary of the cases of DRESS associated with NSAIDs.\r\nRef Year of\r\npublica\u0002tion\r\nSex/age Latency\r\n(days)\r\nDrugs involved Organ\r\ninvolv\u0002ment\r\nEosinophils/mm3 Cutaneous\r\ntests\r\n4 2014 F/45 12 Piroxicam Liver\r\ninsuffiency,\r\nanemia\r\n1870 None\r\n5 2007 M/23 1 Ibuprofen Liver and\r\nkidney failure\r\n500 None\r\n6 2008 F/29 34 Isoniazid\r\nRifampicin\r\nEthambutol\r\nPyrazinamide\r\nLiver 2478 Positive\r\npatch-test to\r\netambuthol and\r\ncelecoxib\r\n42 Celecoxib\r\n7 2014 M/22 hours Ibuprofen Liver failure 4270 None\r\n8 2016 M/11 — Ibuprofen Liver 1560 None\r\n9 2010 F/57 15 Phenylbutazone Liver 2000 None\r\n10 2018 F/38 28 Sulfasalazine Liver,\r\nhemophago\u0002cytic\r\nsyndrom\r\n2810 None\r\n11 2013 M/32 25 Dipyrone Liver and\r\nkidney\r\n3650 Negative*\r\nOur case 2018 F/53 10 Diclofenac Kidney 1830 None\r\nDRESS: drug rash with eosinophilia and systemic symptoms; F: female; NSAIDs: non steroidal anti inflammatory drugs; M: male; Ref:\r\nreferences.\r\n* In this case prick test and intradermal tests were negative and rechallenge test was positive.\r\norganism, leading to the development of specific T cells\r\nagainst them [12].\r\nCross reactions between mefenamic acid, and diclofenac\r\nremains possible. Indeed, co-sensitizations to different\r\nclasses of drugs administered at the onset of DRESS were\r\nfrequent in DRESS, estimated at 18% of cases [13].\r\nIn our case, patch test would be helpful but the patient\r\ndeclined.\r\nTo our knowledge, this is the first case of DRESS syndrome\r\ninduced by diclofenac.\r\nDisclosure of interest\r\nThe authors declare that they have no competing interest.\r\nReferences\r\n[1] Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolym\u0002phoma and drug-induced hypersensitivity syndrome (drug rash\r\nwith eosinophilia and systemic symptoms: DRESS). Semin Cutan\r\nMed Surg 1996;15:250—7.\r\n[2] Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davi\u0002dovici BB, Mockenhaupt M, et al. Variability in the clinical\r\npattern of cutaneous side-effects of drugs with systemic symp\u0002toms: Does a DRESS syndrome really exist? Br J Dermatol\r\n2007;156:609—11.\r\n[3] Miremont Salamé G, Théophie G, Haramburu F, Bégaud B.\r\nCausality assessment in pharmacovigilance: the French method\r\nand its successive updates. Therapie 2016;71:179—86.\r\n[4] Bizid S, Haddad W, Ben Abdallah H, Mohamed G, Bouali R,\r\nAbdelli N. Severe acute hepatitis induced by a DRESS syndrome\r\nto piroxicam. Tunis Med 2014;92:417.\r\n[5] Kucharewicz I, Kemona-Chetnik I, Reduta T, Wierzbicka I,\r\nFlisiak R, Bodzenta-Lukaszyk A. Drug rash with eosinophilia and\r\nsystemic symptoms after ibuprofen intake. J Investig Allergol\r\nClin Immunol 2007;17:345—9.\r\n[6] Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, et al.\r\nDrug rash with eosinophilia and systemic symptoms (DRESS)\r\nsyndrome induced by celecoxib and anti-tuberculosis drugs. J\r\nKorean Med Sci 2008;23:521—5.\r\n[7] Roales-Gómez V, Molero AI, Pérez-Amarilla I, Casabona-Francés\r\nS, Rey-Díaz-Rubio E, Catalán M, et al. DRESS syndrome sec\u0002ondary to ibuprofen as a cause of hyperacute liver failure. Rev\r\nEsp Enferm Dig 2014;106:482—6.\r\n[8] Koca T, Akcam M. Ibuprofen induced DRESS syndrome in a child.\r\nIndian Pediatr 2016;53:745.\r\n[9] Schmutz JL, Barbaud A, Trechot P. Phenylbutazone and DRESS\r\nsyndrome. Ann Dermatol Venereol 2010;137:857.\r\n[10] Liang J, Qu H, Wang X, Wang A, Liu L, Tu P, et al. Drug reac\u0002tion with eosinophilia and systemic symptoms associated with\r\nreactivation of Epstein-Barr virus and/or cytomegalovirus lead\u0002ing to hemophagocytic syndrome in one of two patients. Ann\r\nDermatol 2018;30:71—4.\r\n[11] Díaz MA, Calaforra S, Almero R, Pujol C, de Rojas HF. A case of\r\nDRESS syndrome induced by dipyrone. J Investig Allergol Clin\r\nImmunol 2013;23:139—40.\r\n[12] Gaig P, García-Ortega P, Baltasar M, Bartra J. Drug neosen\u0002sitization during anticonvulsant hypersensitivity syndrome. J\r\nInvestig Allergol Clin Immunol 2006;16:321—6.\r\nDiclofenac induced drug rash with eosinophilia and systemic symptoms 553\r\n[13] Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel\u0002Audran M, et al. Multicentre study to determine the value\r\nand safety of drug patch tests for the three main classes\r\nof severe cutaneous adverse drug reactions. Br J Dermatol\r\n2013;168:555—62.\r\nOns Charfia,b,∗, Imen Aouinti a,b,\r\nAhmed Zaiema,b, Ghozlane Lakhouaa,b,\r\nSihem El Aidli a,b, Sarrah Kastalli a,b\r\na National center of pharmacovigilance, 1006\r\nTunis, Tunisia b Tunis El Manar university, faculty of medicine,\r\nunité de recherche : UR17ES12, 15, rue\r\nDjebel-Lakhdhar, La Rabta, 1007 Tunis, Tunisia\r\n∗ Corresponding author. National center of\r\npharmacovigilance, 9, avenue du\r\nDr-Zouhaier-Essafi, 1006 Tunis, Tunisia.\r\nE-mail address: ons.charfi@gmail.com (O. Charfi)\r\nReceived 9 March 2018;\r\naccepted 3 July 2018\r\nAvailable online 11 July 2018\r\nhttps://doi.org/10.1016/j.therap.2018.07.002\r\n0040-5957/© 2018 Société franc¸aise de pharmacologie et de\r\nthérapeutique. Published by Elsevier Masson SAS. All rights\r\nreserved.\r\n\r\nCharfi O, Aouinti I, Zaiem A, Lakhoua G, El Aidli S, Kastalli S. Diclofenac induced drug rash with eosinophilia and systemic symptoms. Therapie. 2018;73(6):551-553. DOI: 10.1016/j. therap.2018.07.002.\r\n\r\nThis spontaneous case was reported in the medical literature by a health care professional from Tunisia and concerns a 53 years old female patient who experienced a serious adverse reaction of DRESS syndrome and plasmatic creatinine level increased associated with diclofenac. A patient with asthma complained of back pain and she took diclofenac 50 mg daily since January 2018. Ten days after starting the treatment, she presented with fever, cough and multiple lymphadenopathy. She stopped diclofenac and was prescribed amoxicillin, paracetamol, mefenamic acid and cetirizine. One day following the first intake of these drugs, she developed generalized rash involving the trunk and the members. She was admitted to the hospital. Clinical examination revealed temperature at 39.5 ◦C, generalized maculopapular pruritic rash, cervical, axillary and inguinal lymph nodes. Blood tests showed high white blood cells count 13490/mm3 and 1830/mm3 eosinophils. Plasmatic creatinine level was increased at 213 micromol/L. Liver enzymes were normal. Serology for Epstein Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) were negative.\r\n\r\n",{"entities":[[10,14,"REACTIONSTARTDATE"],[214,228,"PRIMARYSOURCEREACTION"],[1086,1097,"PATIENTONSETAGE"],[1098,1103,"PATIENTSEX"],[1131,1141,"MEDICALHISTORYEPISODE"],[1155,1165,"SUSPECTPRODUCT"],[1166,1168,"DRUGSTRUCTUREDOSAGENUMB"],[1169,1171,"DRUGSTRUCTUREDOSAGEUNIT"],[1172,1177,"DRUGINTERVALDOSAGEDEFINITION"],[1181,1194,"DRUGSTARTPERIODUNIT"],[1564,1571,"PRIMARYSOURCECOUNTRY"],[1658,1667,"SERIOUSNESSHOSPITALIZATION"],[1699,1710,"TESTNAME"],[1836,1859,"TESTNAME"],[1861,1870,"TESTRESULT"],[1875,1883,"TESTRESULT"],[1884,1896,"TESTNAME"],[1954,1967,"TESTNAME"],[1974,1981,"TESTRESULT"],[2049,2077,"TESTNAME"],[2079,2082,"TESTNAME"],[2089,2099,"TESTRESULT"],[2101,2122,"TESTNAME"],[2128,2160,"TESTRESULT"],[4503,4507,"REACTIONENDDATE"],[4860,4877,"TESTNAME"],[8204,8240,"REPORTERORGANIZATION"],[8255,8262,"REPORTERCOUNTRY"],[8265,8270,"REPORTERCITY"],[8499,8503,"REPORTERPOSTCODE"],[8828,9028,"LITERATURE REFERENCE"],[9244,9280,"PRIMARYSOURCEREACTION"],[9324,9330,"MEDICALHISTORYEPISODE"],[9988,10014,"TESTNAME"],[10032,10035,"TESTRESULT"],[10036,10047,"TESTUNIT"]]}],["Therapie (2018) 73, 551—553\r\nAvailable online at\r\nwww.sciencedirect.com\r\nLETTER TO THE EDITOR\r\nDiclofenac induced drug rash with\r\neosinophilia and systemic symptoms\u0002\r\nKEYWORDS\r\nDiclofenac;\r\nAdverse drug reaction;\r\nDRESS syndrome;\r\nPharmacovigilance\r\nAbbreviations\r\nDRESS drug rash with eosinophilia and systemic symptoms\r\nCMV cytomegalovirus\r\nEBV Epstien Barr virus\r\nHIV human immunodeficiency virus\r\nNSAID non steroidal anti-inflammatory (drugs)\r\nRegiSCAR European registry of severe cutaneous adverse\r\nreactions\r\nIntroduction\r\nDrug rash with eosinophilia and systemic symptoms (DRESS)\r\nsyndrome is a severe, potentially life-threatening condition\r\nwith a mortality rate of about 10%. This syndrome is charac\u0002terized by the clinical association of fever, rash, and internal\r\norgan involvement [1]. It has been associated with aromatic\r\nanticonvulsants, sulfonamides and allopurinol.\r\nNon steroidal anti inflammatory (NSAI) drugs have been\r\nrarely reported as a causative agent in DRESS syndrome.\r\nWe report the first case of DRESS syndrome associated\r\nwith diclofenac.\r\nCase report\r\nA 53-year-old woman, with asthma complained of back\r\npain and she took diclofenac 50 mg daily on January 2018.\r\nTen days after starting the treatment, she presented with\r\nfever, cough and multiple lymphadenopathy. She stopped\r\ndiclofenac and was prescribed amoxicilline, paracetamol,\r\nmefenamic acid and cetirizine. One day following the first\r\nintake of these drugs, she developed generalized rash\r\n\u0002 This case was notified to the Tunisian center of pharmacovigi\u0002lance of Tunis (Tunisia) on January 30th 2018.\r\ninvolving the trunk and the members. She was admitted to\r\nthe hospital.\r\nClinical examination revealed temperature at 39.5 ◦C,\r\ngeneralized maculopapular pruritic rash, cervical, axillary\r\nand inguinal lymph nodes.\r\nBlood tests showed high white blood cells count\r\n13490/mm3 and 1830/mm3 eosinophils. Plasmatic creati\u0002nine level was increased at 213 \u0002mol/L. Liver enzymes were\r\nnormal.\r\nSerology for Epstein Barr virus (EBV), cytomegalovirus\r\n(CMV) and human immunodeficiency virus (HIV) were neg\u0002ative.\r\nHistological findings were compatible with DRESS syn\u0002drome.\r\nDRESS syndrome was confirmed and all the medications\r\nwere stopped except cetirizine.\r\nSkin condition improved slowly and laboratory parame\u0002ters returned to normal level in about 16 days.\r\nDiscussion\r\nThe diagnosis of DRESS syndrome was made in this patient\r\nbased on the criteria adopted by the European registry of\r\nsevere cutaneous adverse reactions group (RegiSCAR) [2]. In\r\nour case, the RegiScar score was 5 (probable case): general\u0002ized skin rash (1), eosinophilia (2), kidney involvement (1)\r\nenlarged lymph nodes (1).\r\nDiclofenac was suspected to be the responsible drug\r\nfor the DRESS syndrome in this case based on the French\r\nmethod of imputation [3]. The score for diclofenac was\r\nI2.\r\nIn literature, NSAIDs have been rarely reported with\r\nDRESS syndrome as a causative agents [4—11]. It was associ\u0002ated with piroxicam, ibuprofen, celecoxib, phenylbutazone,\r\nsulfasalazine and dipyrone (Table 1).\r\nIn the case reported by Lee, patch tests were positive to\r\nboth celecoxib and ethambutol [6]. The authors could not\r\nconclude about responsibility of the two drugs in inducing\r\nDRESS syndrome.\r\nAs our patient developed hypersensitivity one day after\r\nstarting amoxicilline, paracetamol, mefenamic acid and cet\u0002irizine, a possible co-sensitization with diclofenac remains\r\npossible despite the short delay.\r\nIt has been suggested that DRESS episode may induce\r\na massive non-specific activation of the immune system,\r\nwhich will provide the enhanced expression of costimulatory\r\nmolecules and proinflammatory cytokines. The latter will\r\nallow a more efficient presentation of chemical antigens\r\nto antigen-presenting cells and consequently decrease\r\nthe level of tolerance to drugs present at the time in the\r\n552 Letter to the Editor\r\nTable 1 Summary of the cases of DRESS associated with NSAIDs.\r\nRef Year of\r\npublica\u0002tion\r\nSex/age Latency\r\n(days)\r\nDrugs involved Organ\r\ninvolv\u0002ment\r\nEosinophils/mm3 Cutaneous\r\ntests\r\n4 2014 F/45 12 Piroxicam Liver\r\ninsuffiency,\r\nanemia\r\n1870 None\r\n5 2007 M/23 1 Ibuprofen Liver and\r\nkidney failure\r\n500 None\r\n6 2008 F/29 34 Isoniazid\r\nRifampicin\r\nEthambutol\r\nPyrazinamide\r\nLiver 2478 Positive\r\npatch-test to\r\netambuthol and\r\ncelecoxib\r\n42 Celecoxib\r\n7 2014 M/22 hours Ibuprofen Liver failure 4270 None\r\n8 2016 M/11 — Ibuprofen Liver 1560 None\r\n9 2010 F/57 15 Phenylbutazone Liver 2000 None\r\n10 2018 F/38 28 Sulfasalazine Liver,\r\nhemophago\u0002cytic\r\nsyndrom\r\n2810 None\r\n11 2013 M/32 25 Dipyrone Liver and\r\nkidney\r\n3650 Negative*\r\nOur case 2018 F/53 10 Diclofenac Kidney 1830 None\r\nDRESS: drug rash with eosinophilia and systemic symptoms; F: female; NSAIDs: non steroidal anti inflammatory drugs; M: male; Ref:\r\nreferences.\r\n* In this case prick test and intradermal tests were negative and rechallenge test was positive.\r\norganism, leading to the development of specific T cells\r\nagainst them [12].\r\nCross reactions between mefenamic acid, and diclofenac\r\nremains possible. Indeed, co-sensitizations to different\r\nclasses of drugs administered at the onset of DRESS were\r\nfrequent in DRESS, estimated at 18% of cases [13].\r\nIn our case, patch test would be helpful but the patient\r\ndeclined.\r\nTo our knowledge, this is the first case of DRESS syndrome\r\ninduced by diclofenac.\r\nDisclosure of interest\r\nThe authors declare that they have no competing interest.\r\nReferences\r\n[1] Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolym\u0002phoma and drug-induced hypersensitivity syndrome (drug rash\r\nwith eosinophilia and systemic symptoms: DRESS). Semin Cutan\r\nMed Surg 1996;15:250—7.\r\n[2] Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davi\u0002dovici BB, Mockenhaupt M, et al. Variability in the clinical\r\npattern of cutaneous side-effects of drugs with systemic symp\u0002toms: Does a DRESS syndrome really exist? Br J Dermatol\r\n2007;156:609—11.\r\n[3] Miremont Salamé G, Théophie G, Haramburu F, Bégaud B.\r\nCausality assessment in pharmacovigilance: the French method\r\nand its successive updates. Therapie 2016;71:179—86.\r\n[4] Bizid S, Haddad W, Ben Abdallah H, Mohamed G, Bouali R,\r\nAbdelli N. Severe acute hepatitis induced by a DRESS syndrome\r\nto piroxicam. Tunis Med 2014;92:417.\r\n[5] Kucharewicz I, Kemona-Chetnik I, Reduta T, Wierzbicka I,\r\nFlisiak R, Bodzenta-Lukaszyk A. Drug rash with eosinophilia and\r\nsystemic symptoms after ibuprofen intake. J Investig Allergol\r\nClin Immunol 2007;17:345—9.\r\n[6] Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, et al.\r\nDrug rash with eosinophilia and systemic symptoms (DRESS)\r\nsyndrome induced by celecoxib and anti-tuberculosis drugs. J\r\nKorean Med Sci 2008;23:521—5.\r\n[7] Roales-Gómez V, Molero AI, Pérez-Amarilla I, Casabona-Francés\r\nS, Rey-Díaz-Rubio E, Catalán M, et al. DRESS syndrome sec\u0002ondary to ibuprofen as a cause of hyperacute liver failure. Rev\r\nEsp Enferm Dig 2014;106:482—6.\r\n[8] Koca T, Akcam M. Ibuprofen induced DRESS syndrome in a child.\r\nIndian Pediatr 2016;53:745.\r\n[9] Schmutz JL, Barbaud A, Trechot P. Phenylbutazone and DRESS\r\nsyndrome. Ann Dermatol Venereol 2010;137:857.\r\n[10] Liang J, Qu H, Wang X, Wang A, Liu L, Tu P, et al. Drug reac\u0002tion with eosinophilia and systemic symptoms associated with\r\nreactivation of Epstein-Barr virus and/or cytomegalovirus lead\u0002ing to hemophagocytic syndrome in one of two patients. Ann\r\nDermatol 2018;30:71—4.\r\n[11] Díaz MA, Calaforra S, Almero R, Pujol C, de Rojas HF. A case of\r\nDRESS syndrome induced by dipyrone. J Investig Allergol Clin\r\nImmunol 2013;23:139—40.\r\n[12] Gaig P, García-Ortega P, Baltasar M, Bartra J. Drug neosen\u0002sitization during anticonvulsant hypersensitivity syndrome. J\r\nInvestig Allergol Clin Immunol 2006;16:321—6.\r\nDiclofenac induced drug rash with eosinophilia and systemic symptoms 553\r\n[13] Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel\u0002Audran M, et al. Multicentre study to determine the value\r\nand safety of drug patch tests for the three main classes\r\nof severe cutaneous adverse drug reactions. Br J Dermatol\r\n2013;168:555—62.\r\nOns Charfia,b,∗, Imen Aouinti a,b,\r\nAhmed Zaiema,b, Ghozlane Lakhouaa,b,\r\nSihem El Aidli a,b, Sarrah Kastalli a,b\r\na National center of pharmacovigilance, 1006\r\nTunis, Tunisia b Tunis El Manar university, faculty of medicine,\r\nunité de recherche : UR17ES12, 15, rue\r\nDjebel-Lakhdhar, La Rabta, 1007 Tunis, Tunisia\r\n∗ Corresponding author. National center of\r\npharmacovigilance, 9, avenue du\r\nDr-Zouhaier-Essafi, 1006 Tunis, Tunisia.\r\nE-mail address: ons.charfi@gmail.com (O. Charfi)\r\nReceived 9 March 2018;\r\naccepted 3 July 2018\r\nAvailable online 11 July 2018\r\nhttps://doi.org/10.1016/j.therap.2018.07.002\r\n0040-5957/© 2018 Société franc¸aise de pharmacologie et de\r\nthérapeutique. Published by Elsevier Masson SAS. All rights\r\nreserved.\r\n\r\nCharfi O, Aouinti I, Zaiem A, Lakhoua G, El Aidli S, Kastalli S. Diclofenac induced drug rash with eosinophilia and systemic symptoms. Therapie. 2018;73(6):551-553. DOI: 10.1016/j. therap.2018.07.002.\r\n\r\nThis spontaneous case was reported in the medical literature by a health care professional from Tunisia and concerns a 53 years old female patient who experienced a serious adverse reaction of DRESS syndrome and plasmatic creatinine level increased associated with diclofenac. A patient with asthma complained of back pain and she took diclofenac 50 mg daily since January 2018. Ten days after starting the treatment, she presented with fever, cough and multiple lymphadenopathy. She stopped diclofenac and was prescribed amoxicillin, paracetamol, mefenamic acid and cetirizine. One day following the first intake of these drugs, she developed generalized rash involving the trunk and the members. She was admitted to the hospital. Clinical examination revealed temperature at 39.5 ◦C, generalized maculopapular pruritic rash, cervical, axillary and inguinal lymph nodes. Blood tests showed high white blood cells count 13490/mm3 and 1830/mm3 eosinophils. Plasmatic creatinine level was increased at 213 micromol/L. Liver enzymes were normal. Serology for Epstein Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) were negative.\r\n\r\n",{"entities":[[10,14,"REACTIONSTARTDATE"],[214,228,"PRIMARYSOURCEREACTION"],[1086,1097,"PATIENTONSETAGE"],[1098,1103,"PATIENTSEX"],[1131,1141,"MEDICALHISTORYEPISODE"],[1155,1165,"SUSPECTPRODUCT"],[1166,1168,"DRUGSTRUCTUREDOSAGENUMB"],[1169,1171,"DRUGSTRUCTUREDOSAGEUNIT"],[1172,1177,"DRUGINTERVALDOSAGEDEFINITION"],[1181,1194,"DRUGSTARTPERIODUNIT"],[1211,1219,"DRUGSTARTPERIODUNIT"],[1564,1571,"PRIMARYSOURCECOUNTRY"],[1658,1667,"SERIOUSNESSHOSPITALIZATION"],[1699,1710,"TESTNAME"],[1836,1859,"TESTNAME"],[1861,1870,"TESTRESULT"],[1875,1883,"TESTRESULT"],[1884,1896,"TESTNAME"],[1954,1967,"TESTNAME"],[1974,1981,"TESTRESULT"],[2049,2077,"TESTNAME"],[2079,2082,"TESTNAME"],[2089,2099,"TESTRESULT"],[2101,2122,"TESTNAME"],[2128,2160,"TESTRESULT"],[4503,4507,"REACTIONENDDATE"],[4860,4877,"TESTNAME"],[8204,8240,"REPORTERORGANIZATION"],[8255,8262,"REPORTERCOUNTRY"],[8265,8270,"REPORTERCITY"],[8499,8503,"REPORTERPOSTCODE"],[8828,9028,"LITERATURE REFERENCE"],[9244,9280,"PRIMARYSOURCEREACTION"],[9324,9330,"MEDICALHISTORYEPISODE"],[9988,10014,"TESTNAME"],[10032,10035,"TESTRESULT"],[10036,10047,"TESTUNIT"]]}]]}